Five-time Grammy Award winner and noted music industry executive Clive Davis will receive the Spirit of Hope Award at the annual Multiple Myeloma Research Foundation Fall Gala on Oct. 27, in Greenwich.

Funds raised at the gala will be used to support the development of life-extending treatments for multiple myeloma, an incurable blood cancer.

"Far too many families have been devastated by multiple myeloma and other uncommon cancers that unfortunately have few treatment options available and remain incurable," said Davis, chief creative officer of Sony Music Entertainment. "The MMRF has a proven track record in bringing patients new treatments that have extended their lives. It is my hope that funds raised during this very impressive event will help the MMRF advance its vital work, benefitting not only patients with multiple myeloma, but, by extension, patients with other uncommon cancers."

One of the highlights of the evening will be a star-studded tribute concert in Davis' honor. "We are thrilled to have Clive Davis, an innovator, a legend, and a true pioneer, join what promises to be an unforgettable night," said Kathy Giusti, founder and CEO of the MMRF and a myeloma patient. "Clive's generous support and that of the artists performing in his honor will help the MMRF continue our dedicated leadership in bringing patients battling orphan cancers like multiple myeloma the treatments they so urgently need."

The MMRF's longstanding industry partner, N. Anthony Coles, M.D., president and CEO of Onyx Pharmaceuticals, will receive the Corporate Leadership Award. Under Coles' leadership, Onyx has worked closely with the MMRF to advance carfilzomib from clinical testing to helping patients with the greatest need access this promising treatment through the Carfilzomib Myeloma Access Program, the first expanded access program for patients with multiple myeloma offered in more than five years. In addition, Onyx has worked closely with the MMRF to launch a groundbreaking study that aims to predict multiple myeloma disease progression and patients' response to treatment based on their genomic or molecular profiles.

"The MMRF is widely recognized for its leadership in accelerating the development of transformative treatments for multiple myeloma, and Onyx is proud to consider them among our most trusted and valuable partners," said Coles. "We at Onyx have no doubt that the collaborations built by the MMRF will lead to the development of treatment options that significantly extend patients' lives and vastly improve the outlook of all those living with the disease."

More Information

Fact box

For information and reservations, e-mail or call 888-584-5463.